+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 17Years
All Genders
ID07042126

Phase 3 Study of 611 Injection to Treat Moderate to Severe Atopic Dermatitis in Chinese Adolescents Ages 12 to 17

Led by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Updated on 2025-11-18

180

Participants Needed

3

Research Sites

65 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of 611, a recombinant humanized anti-interleukin-4 receptor alpha IgG4 monoclonal antibody, in Chinese adolescents aged 12 to under 18 years with moderate to severe atopic dermatitis. This Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial aims to assess how well 611 works and its safety in this population. The study is sponsored by Sunshine Guojian Pharmaceutical Shanghai Co., Ltd. and addresses the need for new treatments for adolescents with atopic dermatitis who have not responded well to topical therapies. The study lasts up to 64 weeks and includes several phases a screening period of up to 4 weeks, a 16-week double-blind treatment period where participants receive either 611 or a matching placebo by subcutaneous injection every two weeks, followed by a 36-week maintenance treatment period where 611 is given every two or three weeks. Participants in the placebo group receive a loading dose at week 16 before maintenance treatment. After treatment, there is an 8-week follow-up period. During the study, participants will have regular assessments including the Eczema Area and Severity Index EASI and Investigators Global Assessment IGA to measure skin improvement. Researchers will also track pruritus severity using a numerical rating scale. Safety will be closely monitored throughout, and participants will be asked to use a stable dose of moisturizer twice daily. The primary outcome focuses on achieving significant improvement in eczema severity at week 16. The study ensures ongoing observation and evaluation through week 60 and includes collection of medical history, questionnaires, and laboratory tests to monitor health and treatment effects.

CONDITIONS

Brief Title

Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis

Research Team

Q

Qinghong Zhou, Master

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here